Panel Discusses Direction Of Alzheimer’s Disease Research

by Ket Patel | Sep 17, 2012 | Slider Content

Neurologists Dr. Richard Caselli and Dr. Marwan Sabbagh discuss the direction of Alzheimer’s disease research and some of the hot topics at the 2012 Alzheimer’s Association International Conference in Vancouver, B.C. Some of the latest developments under discussion at...

FDA Approves Oral MS Drug Teriflunomide

by Ket Patel | Sep 16, 2012 | All Articles For Neurology, Multiple Sclerosis

The Food and Drug Administration has approved the latest oral therapy for relapsing multiple sclerosis, teriflunomide (Aubagio), but it will carry a strong warning that it increases the risk of fetal harm. The drug, made by the Genzyme division of Sanofi Aventis, is...

CombiRx For MS Not Better Than Monotherapy

by Ket Patel | Sep 12, 2012 | All Articles For Neurology, Multiple Sclerosis

Glatiramer acetate and interferon beta-1a used in combination were no more effective for patients with relapsing-remitting multiple sclerosis than were either agent alone in a 3-year, randomized trial. On quality of life measures, monotherapy and combination therapy...

Is there A Multiple Sclerosis Epidemic And Is It The Result Of A Plethora Of Etiological Factors Or Of An As Yet Unknown Or Emergent Latent Risk Factor?

by Ket Patel | Sep 11, 2012 | All Articles For Neurology, Multiple Sclerosis

Bernd Krone, Institute of Virology, University Göttingen, Göttingen, Germany, and Laboratory Medicine Institute Kassel, Druseltalstrasse 61, 34131 Kassel, Germany, Email b.krone@staber-kollegen.de A recent epidemiologic study by Ajdacic-Gross et al. might give an...

Why some multiple sclerosis- patients stop disease modifying treatment in MS and why some don’t start at all

by Ket Patel | Sep 11, 2012 | All Articles For Neurology, Multiple Sclerosis

Nina Grytten Torkildsen National Multiple Sclerosis Competence Centre, Dept. of Neurology, Haukeland University Hospital Norway Although everyone with relapsing remitting multiple sclerosis (RRMS) is advised to begin disease modifying therapy (DMT) in accordance with...